Lihling Lin

Lih-ling Lin, as Chief Scientific Officer at PharmaEssentia, plays a pivotal role in shaping the company's innovative trajectory within the biopharmaceutical landscape. With a strategic focus on expanding and diversifying the company's pipeline, she oversees global R&D initiatives that leverage cutting-edge drug development, translational medicine, and biomarker discovery to accelerate the delivery of novel biologics for challenging diseases such as hematology, oncology, and immunology. Under her leadership, PharmaEssentia has advanced multiple pipeline candidates through preclinical and clinical development stages, emphasizing the integration of in vitro and cell biology techniques to optimize therapeutic efficacy and safety profiles.

Lih-ling’s expertise in pharmacology and clinical development ensures that the company’s biologics are not only scientifically robust but also aligned with regulatory standards across critical markets, including the United States. Her strategic initiatives include fostering collaborations with academic institutions and biotech partners to enhance translational research efforts and leverage innovative biomarker strategies for patient stratification and personalized medicine. Her leadership has been instrumental in strengthening PharmaEssentia’s R&D engagement globally, positioning the company as a competitive player in the rapidly evolving biopharmaceutical sector.

Prior to her current role, Lih-ling gained extensive experience at Sanofi in Boston, where she contributed to pioneering projects in oncology and immunology, further honing her expertise in biologics and drug development. Her comprehensive understanding of cell biology, pharmacology, and clinical translation continues to drive PharmaEssentia’s mission to deliver impactful therapies that address unmet medical needs worldwide.